Alterity Therapeutics Limited (PRNAF)
USD 0.01
(0.0%)
USD 0.01
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | -19.12 Million AUD | -38.51% |
| 2023 | -13.8 Million AUD | -7.47% |
| 2022 | -12.84 Million AUD | 16.08% |
| 2021 | -15.3 Million AUD | -52.19% |
| 2020 | -10.05 Million AUD | 18.46% |
| 2019 | -12.33 Million AUD | -49.26% |
| 2018 | -8.26 Million AUD | -9.59% |
| 2017 | -7.54 Million AUD | 2.43% |
| 2016 | -7.72 Million AUD | -31.34% |
| 2015 | -5.88 Million AUD | 55.85% |
| 2014 | -13.32 Million AUD | -71.17% |
| 2013 | -7.78 Million AUD | -48.63% |
| 2012 | -5.23 Million AUD | 18.53% |
| 2011 | -6.43 Million AUD | -31.06% |
| 2010 | -4.9 Million AUD | 34.77% |
| 2009 | -7.52 Million AUD | 44.64% |
| 2008 | -13.58 Million AUD | -21.99% |
| 2007 | -11.14 Million AUD | 5.0% |
| 2006 | -11.72 Million AUD | 52.92% |
| 2005 | -24.9 Million AUD | -153.49% |
| 2004 | -9.82 Million AUD | -114.94% |
| 2003 | -4.57 Million AUD | 16.15% |
| 2002 | -5.45 Million AUD | -31.71% |
| 2001 | -4.13 Million AUD | -212.07% |
| 2000 | -1.32 Million AUD | -1557.86% |
| 1999 | -80 Thousand AUD | -11494.2% |
| 1998 | -690.00 AUD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -6.5 Million AUD | -100.0% |
| 2024 Q1 | -3.25 Million AUD | 43.66% |
| 2024 FY | -19.12 Million AUD | -38.51% |
| 2024 Q4 | -12.61 Million AUD | -100.0% |
| 2024 Q3 | -6.3 Million AUD | 3.06% |
| 2023 Q4 | -5.77 Million AUD | -100.0% |
| 2023 Q3 | -2.88 Million AUD | 64.05% |
| 2023 FY | -13.8 Million AUD | -7.47% |
| 2023 Q1 | -4.01 Million AUD | 35.88% |
| 2023 Q2 | -8.03 Million AUD | -100.0% |
| 2022 Q2 | -6.58 Million AUD | -100.0% |
| 2022 Q4 | -6.26 Million AUD | -100.0% |
| 2022 Q3 | -3.13 Million AUD | 52.43% |
| 2022 Q1 | -3.29 Million AUD | 51.21% |
| 2022 FY | -12.84 Million AUD | 16.08% |
| 2021 Q1 | -4.28 Million AUD | 45.23% |
| 2021 Q3 | -3.37 Million AUD | 60.6% |
| 2021 FY | -15.3 Million AUD | -52.19% |
| 2021 Q4 | -6.74 Million AUD | -100.0% |
| 2021 Q2 | -8.56 Million AUD | -100.0% |
| 2020 FY | -10.05 Million AUD | 18.46% |
| 2020 Q4 | -7.81 Million AUD | -100.0% |
| 2020 Q1 | -2.82 Million AUD | 59.7% |
| 2020 Q2 | -5.64 Million AUD | -100.0% |
| 2020 Q3 | -3.9 Million AUD | 30.71% |
| 2019 Q3 | -3.49 Million AUD | -31.04% |
| 2019 Q4 | -6.99 Million AUD | -100.0% |
| 2019 FY | -12.33 Million AUD | -49.26% |
| 2019 Q2 | -2.67 Million AUD | 0.0% |
| 2019 Q1 | -2.67 Million AUD | -14.89% |
| 2018 FY | -8.26 Million AUD | -9.59% |
| 2018 Q1 | -1.8 Million AUD | 7.01% |
| 2018 Q4 | -2.32 Million AUD | 0.0% |
| 2018 Q3 | -2.32 Million AUD | -28.5% |
| 2018 Q2 | -1.8 Million AUD | 0.0% |
| 2017 Q2 | -1.82 Million AUD | 0.0% |
| 2017 FY | -7.54 Million AUD | 2.43% |
| 2017 Q4 | -1.94 Million AUD | 0.0% |
| 2017 Q3 | -1.94 Million AUD | -6.53% |
| 2017 Q1 | -1.82 Million AUD | 25.09% |
| 2016 Q3 | -2.43 Million AUD | -70.75% |
| 2016 Q2 | -1.42 Million AUD | 0.0% |
| 2016 Q1 | -1.42 Million AUD | 38.37% |
| 2016 Q4 | -2.43 Million AUD | 0.0% |
| 2016 FY | -7.72 Million AUD | -31.34% |
| 2015 FY | -5.88 Million AUD | 55.85% |
| 2015 Q3 | -2.31 Million AUD | -269.79% |
| 2015 Q4 | -2.31 Million AUD | 0.0% |
| 2015 Q2 | -626.34 Thousand AUD | 0.0% |
| 2015 Q1 | -626.34 Thousand AUD | 76.81% |
| 2014 Q2 | -3.96 Million AUD | 0.0% |
| 2014 Q4 | -2.7 Million AUD | 0.0% |
| 2014 FY | -13.32 Million AUD | -71.17% |
| 2014 Q3 | -2.7 Million AUD | 31.88% |
| 2014 Q1 | -3.96 Million AUD | -129.48% |
| 2013 Q3 | -1.72 Million AUD | 0.0% |
| 2013 FY | -7.78 Million AUD | -48.63% |
| 2013 Q4 | -1.72 Million AUD | 0.0% |
| 2012 FY | -5.23 Million AUD | 18.53% |
| 2011 FY | -6.43 Million AUD | -31.06% |
| 2010 FY | -4.9 Million AUD | 34.77% |
| 2009 FY | -7.52 Million AUD | 44.64% |
| 2008 Q2 | -5.04 Million AUD | 0.04% |
| 2008 FY | -13.58 Million AUD | -21.99% |
| 2008 Q4 | -1.74 Million AUD | 7.92% |
| 2008 Q3 | -1.9 Million AUD | 62.35% |
| 2008 Q1 | -5.04 Million AUD | -202.94% |
| 2007 FY | -11.14 Million AUD | 5.0% |
| 2007 Q4 | -1.66 Million AUD | 0.44% |
| 2007 Q3 | -1.67 Million AUD | 57.1% |
| 2007 Q2 | -3.9 Million AUD | -0.23% |
| 2007 Q1 | -3.89 Million AUD | -32.94% |
| 2006 Q2 | -2.55 Million AUD | -0.01% |
| 2006 Q1 | -2.55 Million AUD | 70.87% |
| 2006 Q3 | -2.93 Million AUD | -14.77% |
| 2006 Q4 | -2.92 Million AUD | 0.12% |
| 2006 FY | -11.72 Million AUD | 52.92% |
| 2005 Q2 | -3.57 Million AUD | -0.1% |
| 2005 FY | -24.9 Million AUD | -153.49% |
| 2005 Q1 | -3.56 Million AUD | -22.07% |
| 2005 Q4 | -8.76 Million AUD | 1.68% |
| 2005 Q3 | -8.91 Million AUD | -149.67% |
| 2004 Q4 | -2.92 Million AUD | 0.58% |
| 2004 FY | -9.82 Million AUD | -114.94% |
| 2004 Q1 | -2.01 Million AUD | 0.16% |
| 2004 Q2 | -2.01 Million AUD | 0.03% |
| 2004 Q3 | -2.94 Million AUD | -45.68% |
| 2003 FY | -4.57 Million AUD | 16.15% |
| 2003 Q2 | -1.56 Million AUD | 3.19% |
| 2003 Q1 | -1.62 Million AUD | 0.0% |
| 2003 Q3 | 364.8 Thousand AUD | 123.24% |
| 2003 Q4 | -2.02 Million AUD | -654.41% |
| 2002 FY | -5.45 Million AUD | -31.71% |
| 2001 FY | -4.13 Million AUD | -212.07% |
| 2000 FY | -1.32 Million AUD | -1557.86% |
| 1999 FY | -80 Thousand AUD | -11494.2% |
| 1998 FY | -690.00 AUD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Evofem Biosciences, Inc. | 52.97 Million USD | 136.096% |
| Arch Therapeutics, Inc. | -6.98 Million USD | -173.864% |
| CSL Limited | 2.64 Billion USD | 100.724% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 129.361% |
| Regen BioPharma, Inc. | 1.02 Million USD | 1968.424% |
| BioStem Technologies, Inc. | -8.48 Million USD | -125.433% |
| Capstone Therapeutics Corp. | -3.81 Million USD | -400.745% |
| Qrons Inc. | -789.34 Thousand USD | -2322.694% |
| Nascent Biotech, Inc. | -2.08 Million USD | -816.014% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 69.451% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | -141.974% |
| Skye Bioscience, Inc. | -37.64 Million USD | 49.2% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -4502.751% |
| Rebus Holdings, Inc. | -1.02 Million USD | -1774.849% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | -20.49% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -1332.007% |
| Genscript Biotech Corporation | -95.47 Million USD | 79.971% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -2923.917% |
| Adynxx, Inc. | - USD | Infinity% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 74.489% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | -190.802% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -6894.632% |
| SQZ Biotechnologies Company | -79.46 Million USD | 75.934% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -561.164% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -950.435% |
| Mesoblast Limited | -87.95 Million USD | 78.258% |
| Marizyme, Inc. | -65.34 Million USD | 70.735% |
| Genus plc | 7.9 Million USD | 342.069% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | -75.578% |
| Pharming Group N.V. | -10.54 Million USD | -81.299% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -781.341% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -415.425% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | -116.231% |
| ContraFect Corporation | -65.15 Million USD | 70.648% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | -291.388% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -1007.031% |
| IMV Inc. | -36.48 Million USD | 47.586% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | -137.273% |
| MultiCell Technologies, Inc. | -380.07 USD | -5031463.659% |
| ONE Bio Corp. | 8.67 Million USD | 320.402% |
| Accustem Sciences Inc. | -3.74 Million USD | -410.446% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 63.005% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -1409.19% |
| Q BioMed Inc. | -2.05 Million USD | -831.9% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -412.281% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -703.213% |
| Biomind Labs Inc. | -1.21 Million USD | -1474.83% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 67.981% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -516.534% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -881.068% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -127594.071% |
| Curative Biotechnology, Inc. | -5.81 Million USD | -228.737% |
| GB Sciences, Inc. | -1.36 Million USD | -1304.405% |
| Alpha Cognition Inc. | -13.77 Million USD | -38.852% |
| HST Global, Inc. | -146.21 Thousand USD | -12979.45% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -989.798% |
| Halberd Corporation | -79.67 Thousand USD | -23901.536% |
| Enzolytics Inc. | -2.17 Million USD | -778.5% |
| Agentix Corp. | -1.37 Million USD | -1291.596% |
| Resverlogix Corp. | -3.61 Million USD | -429.736% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -502.991% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 93.519% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 19613.739% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 376.167% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -381.336% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -531.944% |
| AVAX Technologies, Inc. | -6.41 Million USD | -198.168% |
| Zenith Capital Corp. | -10.59 Million USD | -80.478% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -82179.769% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -361.258% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -31540.091% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -853.734% |
| Kadimastem Ltd | -3.3 Million USD | -478.203% |
| Helix BioMedix, Inc. | -1.05 Million USD | -1710.836% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -4232.761% |
| LadRx Corporation | 400.44 Thousand USD | 4875.577% |
| Cell Source, Inc. | -5.32 Million USD | -259.382% |
| Regen BioPharma, Inc. | 1.02 Million USD | 1968.424% |
| NovAccess Global Inc. | -4.76 Million USD | -300.98% |
| Affymax, Inc. | -14.42 Million USD | -32.581% |
| Itoco Inc. | -1.86 Million USD | -923.195% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | -330.463% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -1045.804% |
| Mobile Lads Corp. | -2.26 Million USD | -744.94% |
| CytoDyn Inc. | -49.84 Million USD | 61.631% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -24096.809% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -8282.815% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -1931.107% |
| SYBLEU INC | -180.3 Thousand USD | -10506.234% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -1085.777% |
| International Stem Cell Corporation | -131 Thousand USD | -14498.064% |
| Bioxytran, Inc. | -4.28 Million USD | -346.81% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -35136.335% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -655.794% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 60.219% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -804.61% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -2348.941% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -503.645% |
| Neutra Corp. | -233.46 Thousand USD | -8091.148% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 5.754% |
| PureTech Health plc | -65.69 Million USD | 70.891% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 10.077% |
| IXICO plc | -1.17 Million USD | -1523.384% |
| IntelGenx Technologies Corp. | -9.92 Million USD | -92.641% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 66.525% |
| CSL Limited | 2.64 Billion USD | 100.724% |
| Cellectis S.A. | -103.17 Million USD | 81.465% |